Powered by

Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP); - Milestone represents the first patient dosed with an OTS AdenoVerse immunotherapy targeting infectious disease -

Mar 23, 2021 - PR Newswire

PR Newswire

 Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP) (clinical trial identifier:NCT04724980). The US Food and Drug Administration recently granted...